Target intelligence / Profile preview

Ribosomal protein L23a pseudogene 96 (RPL23AP96)

Target
RPL23AP96
Molecular classification
Other (pseudogene)
01

Overview

Ribosomal protein L23a pseudogene 96 (RPL23AP96) is a pseudogene, meaning it is a non-functional, non-protein-coding copy of the gene encoding ribosomal protein L23a. Pseudogenes such as RPL23AP96 are DNA segments that closely resemble functional genes but have lost their ability to code for functional proteins over evolutionary time due to mutations or genetic drift. This family of pseudogenes is numerous within the human genome, related to the functional RPL23A gene which encodes a component of the 60S large ribosomal subunit. To date, there is no information describing RPL23AP96 as having any biological function, therapeutic relevance, or clinical significance. It is neither considered a protein-coding gene nor a therapeutic target, and there are no known clinical or pharmacological implications associated with this locus. RPL23AP96 is not a drug target, does not code for a protein, and does not have aliases, biological function, disease role, or clinical utility in biomarker, safety, or drug-interaction contexts. It is one of many related pseudogenes derived from the RPL23A ribosomal protein gene.

02

Mechanism of action

None (not a target for drug action)

03

Biological functions

None (pseudogene; does not encode a functional protein)
04

Disease associations

None known (no evidence or literature supporting a disease role for this specific pseudogene)
05

Safety considerations

None specific; pseudogenes generally do not raise therapeutic safety concerns
06

Interacting drugs

None (not a functional protein, thus no known drug interactions)
07

Biomarkers

None currently recognized

Beyond the preview

Go deeper on Ribosomal protein L23a pseudogene 96 (RPL23AP96).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L23a pseudogene 96 (RPL23AP96).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call